Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.57 |
| ▸ | GABRP | O00591 | 2/20 | 0.49 |
| ▸ | GABRD | O14764 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.49 |
| ▸ | GABRE | P78334 | 2/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12382830 | 0.87 | AAK1 (0.39) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL13100683 | 0.86 | GPR3 (0.57) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3339641 | 0.81 | GPR3 (0.55) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL27979888 | 0.81 | GPR3 (0.55) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL23373487 | 0.79 | GPR3 (0.53) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL13301258 | 0.78 | MEN1 (0.49) | KDM4EMAPTALDH1A1HPGDMEN1 | |
| SCHEMBL19432924 | 0.78 | CYP1A2 (0.38) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL8173842 | 0.78 | KDM4E (0.55) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL22099990 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL16621628 | 0.78 | ALKBH5 (0.41) | GPR3GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | claimed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | claimed |
| US-9941422-B2 | Organic photoelectric conversion element and solar cell using the same | Konica Minolta, Inc. (JP) | 2018-04-10 | — | — | US | disclosed |
| US-9941422-B2 | Organic photoelectric conversion element and solar cell using the same | Konica Minolta, Inc. (JP) | 2018-04-10 | — | — | US | disclosed |
| US-9882072-B2 | Solar cell and transparent electrode | Konica Minolta, Inc. (JP) | 2018-01-30 | — | — | US | disclosed |
| US-9882072-B2 | Solar cell and transparent electrode | Konica Minolta, Inc. (JP) | 2018-01-30 | — | — | US | disclosed |
| EP-2125812-B2 | USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-20150221793-A1 | SOLAR CELL AND TRANSPARENT ELECTRODE | Konica Minolta, Inc. (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150096610-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL USING THE SAME | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150096610-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL USING THE SAME | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2015-04-09 | — | — | US | disclosed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | disclosed |
| EP-2125812-B1 | USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| US-4731358-A | β-carbolines and their use as tranquilizers | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, SNCA, CHAT | GPR3 208/4885GABRP 1512/4885GABRD 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.